The objective was to describe the immunological status among children infected with HIV （human immunodeficiency virus） at baseline and their change during the treatment. This longitudinal study conducted at the Cent...The objective was to describe the immunological status among children infected with HIV （human immunodeficiency virus） at baseline and their change during the treatment. This longitudinal study conducted at the Center of Excellence in Lubumbashi from 2nd semester, 2011 to the 2nd semester, 2012, examined the records of children who had been receiving antiretroviral therapy for 48 weeks. A count of CD4 ＋ T lymphocytes was performed at the beginning, 24 weeks, and 48 weeks of treatment. The immunological status was defined by the 1996 CDC （centers for disease control） immunological categories. All the children were on zidovudine, lamivudine/nevirapine or Efavirens. At initiation of treatment, severe immunosuppression was found in 56%, moderative in 28% and lacked in 16% of cases. Furthermore, after 48 weeks of treatment, a change in the immunological status was observed in 42% of cases. In contrast, 58% of cases kept in their original status. In this cohort, the immune status has not undergone significant change.展开更多
文摘The objective was to describe the immunological status among children infected with HIV （human immunodeficiency virus） at baseline and their change during the treatment. This longitudinal study conducted at the Center of Excellence in Lubumbashi from 2nd semester, 2011 to the 2nd semester, 2012, examined the records of children who had been receiving antiretroviral therapy for 48 weeks. A count of CD4 ＋ T lymphocytes was performed at the beginning, 24 weeks, and 48 weeks of treatment. The immunological status was defined by the 1996 CDC （centers for disease control） immunological categories. All the children were on zidovudine, lamivudine/nevirapine or Efavirens. At initiation of treatment, severe immunosuppression was found in 56%, moderative in 28% and lacked in 16% of cases. Furthermore, after 48 weeks of treatment, a change in the immunological status was observed in 42% of cases. In contrast, 58% of cases kept in their original status. In this cohort, the immune status has not undergone significant change.
